Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| A-192621 SCHEMBL29551251 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL7465738 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL3982388 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL22404939 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL3982386 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8176298 | 0.97 | EDNRB (0.94) | EDNRBEDNRA | |
| SCHEMBL8189498 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8189503 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8185019 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8180058 | 0.94 | EDNRB (1.00) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | ENB THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | claimed |
| US-20250082773-A1 | COMBINATION THERAPY USING EXOSOME SECRETION INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Research & Business Foundation Sungkyunkwan University (KR) | 2025-03-13 | — | — | US | claimed |
| US-20250009747-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OR PREVENTING MUSCLE FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-01-09 | — | — | US | claimed |
| WO-2024179362-A1 | METHODS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION SKELETAL SEQUELAE | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2024-09-06 | — | — | WO | claimed |
| EP-4422634-A2 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OR PREVENTING MUSCLE FIBROSIS | Association Institut de Myologie (FR) | 2024-09-04 | — | — | EP | claimed |
| WO-2024141048-A1 | METHODS FOR TREATING CORONAVIRUS INFECTIONS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2024-07-04 | — | — | WO | claimed |
| CN-116726183-A | Compositions and methods for treating cancers associated with ETBR activation | ENB治疗公司 | 2023-09-12 | — | — | CN | claimed |
| CN-108025035-B | Compositions and methods for treating cancers associated with ETBR activation | ENB治疗公司 | 2023-06-13 | — | — | CN | claimed |
| US-20230094832-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING IMMUNE CHECKPOINT INHIBITOR AND EXOSOME SECRETION INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2023-03-30 | — | — | US | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| US-20220265628-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | ENB THERAPEUTICS, INC. | 2022-08-25 | — | — | US | claimed |
| US-20220257700-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | ENB THERAPEUTICS, INC. | 2022-08-18 | — | — | US | claimed |
| EP-3999062-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | ENB Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| CN-114423425-A | Treatment of urothelial and renal cancers by using endothelin B receptor antagonists | ENB治疗公司 | 2022-04-29 | — | — | CN | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-8173593-B2 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2012-05-08 | — | — | US | claimed |
| US-20090203591-A1 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2009-08-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | EDNRB, EDNRA, CASP8 | EDNRB 1/4885EDNRA 2/4885 |
| US-20230094832-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING IMMUNE CHECKPOINT INHIBITOR AND EXOSOME SECRETION INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | EXOSC9, EXOSC5, EXOSC10 | EDNRB 3349/4885EDNRA 3304/4885 |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | EDNRB 659/4885EDNRA 1190/4885 |
| US-20220257700-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | EDNRB, EDNRA, CASP8 | EDNRB 1/4885EDNRA 2/4885 |
| US-20220265628-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | EDNRB, EDNRA, UTS2R | EDNRB 1/4885EDNRA 2/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | EDNRB 1013/4885EDNRA 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.